{"filing":{"accession_number":"0001599298-26-000058","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"smmt-20260722.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/smmt-20260722.htm"},"events":[{"id":19332,"run_id":17393,"accession_number":"0001599298-26-000058","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Summit announced updated overall survival (OS) results from the Phase III HARMONi clinical trial for ivonescimab, showing a hazard ratio of 0.76 in the June 2026 analysis with consistent efficacy across western and Asian patient populations. While this is clinical trial data rather than a formal earnings release or regulatory approval, the results are material to investors because they directly support the company's pending Biologics License Application (BLA) with a PDUFA goal date of November 14, 2026, and demonstrate progress toward potential FDA approval of the company's lead investigational therapy. The disclosure is operational/strategic in nature—reporting clinical development progress—rather than fitting a specific financial, governance, or legal category.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18394,"accession_number":"0001599298-26-000058","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit announced updated overall survival (OS) results from the Phase III HARMONi clinical trial for ivonescimab, showing a hazard ratio of 0.76 in the June 2026 analysis with consistent efficacy across western and Asian patient populations. While this is clinical trial data rather than a formal earnings release or regulatory approval, the results are material to investors because they directly support the company's pending Biologics License Application (BLA) with a PDUFA goal date of November 14, 2026, and demonstrate progress toward potential FDA approval of the company's lead investigational therapy. The disclosure is operational/strategic in nature—reporting clinical development progress—rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:11:38.157139+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18394,"accession_number":"0001599298-26-000058","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit announced updated overall survival (OS) results from the Phase III HARMONi clinical trial for ivonescimab, showing a hazard ratio of 0.76 in the June 2026 analysis with consistent efficacy across western and Asian patient populations. While this is clinical trial data rather than a formal earnings release or regulatory approval, the results are material to investors because they directly support the company's pending Biologics License Application (BLA) with a PDUFA goal date of November 14, 2026, and demonstrate progress toward potential FDA approval of the company's lead investigational therapy. The disclosure is operational/strategic in nature—reporting clinical development progress—rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:11:38.157139+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-22"}]}